Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (<i>n</i> = 38) or intravitreal brolucizumab (...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/9/1164 |
| _version_ | 1797520149388984320 |
|---|---|
| author | Yoshiko Fukuda Yoichi Sakurada Mio Matsubara Yuka Hasebe Atsushi Sugiyama Wataru Kikushima Kenji Kashiwagi |
| author_facet | Yoshiko Fukuda Yoichi Sakurada Mio Matsubara Yuka Hasebe Atsushi Sugiyama Wataru Kikushima Kenji Kashiwagi |
| author_sort | Yoshiko Fukuda |
| collection | DOAJ |
| description | We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (<i>n</i> = 38) or intravitreal brolucizumab (<i>n</i> = 14). Indocyanine green angiography (ICGA) was performed at baseline and at the 3-month visit. Selection of anti-VEGF agents depended on time. In the brolucizumab-treated group, best-corrected visual acuity (BCVA) improved from 0.27 ± 0.34 (log MAR unit) at baseline to 0.20 ± 0.24 at 3-month visit, which is comparable with the aflibercept-treated group (<i>p</i> = 0.87), after adjustment of confounding factors. Central retinal thickness significantly decreased by 43%−44% in both groups. Subfoveal choroidal thickness also significantly decreased by 20.5% during this interval in the brolucizumab-treated group, which was greater than the aflibercept-treated group. The complete resolution rate of polypoidal lesions on ICGA was significantly higher (<i>p</i> = 0.043) in the brolucizumab-treated group (78.6%) than in the aflibercept-treated group (42.1%). Intraocular inflammation was observed in 14.3% (2/14) in the brolucizumab-treated group only. In short-term follow-up, intravitreal injection of 3-monthly brolucizumab was comparable with aflibercept in terms of BCVA and morphological improvement along with higher resolution of polypoidal lesion(s) on ICGA. |
| first_indexed | 2024-03-10T07:52:45Z |
| format | Article |
| id | doaj.art-eadc85eb8f87422eb368bf8144d21ca1 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T07:52:45Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-eadc85eb8f87422eb368bf8144d21ca12023-11-22T12:07:57ZengMDPI AGBiomedicines2227-90592021-09-0199116410.3390/biomedicines9091164Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal VasculopathyYoshiko Fukuda0Yoichi Sakurada1Mio Matsubara2Yuka Hasebe3Atsushi Sugiyama4Wataru Kikushima5Kenji Kashiwagi6Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi 409-3821, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi 409-3821, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi 409-3821, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi 409-3821, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi 409-3821, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi 409-3821, JapanDepartment of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi 409-3821, JapanWe compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (<i>n</i> = 38) or intravitreal brolucizumab (<i>n</i> = 14). Indocyanine green angiography (ICGA) was performed at baseline and at the 3-month visit. Selection of anti-VEGF agents depended on time. In the brolucizumab-treated group, best-corrected visual acuity (BCVA) improved from 0.27 ± 0.34 (log MAR unit) at baseline to 0.20 ± 0.24 at 3-month visit, which is comparable with the aflibercept-treated group (<i>p</i> = 0.87), after adjustment of confounding factors. Central retinal thickness significantly decreased by 43%−44% in both groups. Subfoveal choroidal thickness also significantly decreased by 20.5% during this interval in the brolucizumab-treated group, which was greater than the aflibercept-treated group. The complete resolution rate of polypoidal lesions on ICGA was significantly higher (<i>p</i> = 0.043) in the brolucizumab-treated group (78.6%) than in the aflibercept-treated group (42.1%). Intraocular inflammation was observed in 14.3% (2/14) in the brolucizumab-treated group only. In short-term follow-up, intravitreal injection of 3-monthly brolucizumab was comparable with aflibercept in terms of BCVA and morphological improvement along with higher resolution of polypoidal lesion(s) on ICGA.https://www.mdpi.com/2227-9059/9/9/1164polypoidal choroidal vasculopathybrolucizumabafliberceptintraocular inflammationresolution of polypoidal lesion(s) |
| spellingShingle | Yoshiko Fukuda Yoichi Sakurada Mio Matsubara Yuka Hasebe Atsushi Sugiyama Wataru Kikushima Kenji Kashiwagi Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy Biomedicines polypoidal choroidal vasculopathy brolucizumab aflibercept intraocular inflammation resolution of polypoidal lesion(s) |
| title | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
| title_full | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
| title_fullStr | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
| title_full_unstemmed | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
| title_short | Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy |
| title_sort | comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy |
| topic | polypoidal choroidal vasculopathy brolucizumab aflibercept intraocular inflammation resolution of polypoidal lesion(s) |
| url | https://www.mdpi.com/2227-9059/9/9/1164 |
| work_keys_str_mv | AT yoshikofukuda comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT yoichisakurada comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT miomatsubara comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT yukahasebe comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT atsushisugiyama comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT watarukikushima comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy AT kenjikashiwagi comparisonofoutcomesbetween3monthlybrolucizumabandafliberceptinjectionsforpolypoidalchoroidalvasculopathy |